Nov. 20, 2020, 6:24 p.m.
New Delhi: Pfizer on Friday informed that it is looking forward for an emergency authorization from US regulators to use its covid-19 vaccine candidate which has proved out to be 95 per cent effective in the late stage trials.
It is highly possible that the regulators will grant permission to Pfizer, making it the first vaccine for the US which is the worst-hit country by the pandemic.
In an attempt to mitigate the spread of virus, US regulators have been holding high hopes from vaccine candidates and now that Pfizer and Moderna have announced that their vaccines are highly effective with no adverse effects, the officials may stand by the approval process.
Pfizer, meanwhile, said that their vaccine provides protection and a good safety record which make it eligible for the emergency use authorizatioin and Food and Drug Administration (FDA) should really consider it.
“Our work to deliver a safe and effective vaccine has never been more urgent,” Pfizer CEO Albert Bourla said in a statement.
Pfizer’s vaccine developed with BioNTech aims to produce a total of 50 million doses of their vaccine by the added of 2020. The number is expected to go up to 1.3 billion doses in 2021.
Image Credit: Google